RANI vs NUVL vs PRAX vs LNTH vs ARVN

For growth investors, Lantheus Holdings, Inc.

(LNTH) is the stronger pick with 0. 5% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 27. 3x trailing P/E (17. 7x forward), making it the more compelling value choice. Analysts rate Rani Therapeutics Holdings, Inc. (RANI) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +461. 5%, compared to -91. 2% for Rani Therapeutics Holdings, Inc. (RANI). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus RANI's -91. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 45β versus Rani Therapeutics Holdings, Inc. 's 2. 38β — meaning RANI is approximately 423% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 9% for Rani Therapeutics Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lantheus Holdings, Inc.

(LNTH) is pulling ahead at 0. 5% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -29. 2% for Rani Therapeutics Holdings, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -51. 9% for RANI. At the gross margin level — before operating expenses — RANI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RANI: 1523.

0% to $15. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45)). Rani Therapeutics Holdings, Inc. (RANI) carries a higher beta of 2. 38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +42. 9%, RANI: -91. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.